Performance Indicators of the SARC-F Questionnaire in Acute Care

Sarcopenia Clinical Trial

— SARC-F-CHUB  

Official title:

Performance Indicators of the SARC-F Questionnaire in Acute Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04757454
• Other study ID #: CHUB SARC-F
• Status: Completed
• Start date: September 1, 2019
• Est. completion date: November 11, 2020

Study information

• Verified date: February 2021
• Source: Brugmann University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study applies the Sluggishness, Assistance in walking, Rising from a chair, Climb stairs, Falls (SARC-F) questionnaire in older patients hospitalized in an acute care geriatric unit and aims to determine its performance indicators to screen for sarcopenia according to the revised European Consensus on definition and diagnosis (EWGSOP2) within this population

Description:

Sarcopenia is an age-related disease associated with health adverse outcomes, i.e. higher risk of mobility limitation, falls, fractures, mortality, and lower quality of life. The European Working Group on Sarcopenia has recently revisited one of the widely used most acknowledged definitions and launched the revised European consensus on definition and diagnosis (EWGSOP2) (4). Applying the EWGSOP2 is a three-tier process: first, screening by the Sluggishness, Assistance in walking, Rising from a chair, Climb stairs, Falls (SARC-F) questionnaire; second, diagnosis by low muscle strength, and low muscle mass; third, severity grading by low muscle function. The EWGSOP2 recommends the assessment of sarcopenia in every population, both in community-dwelling and acute care older patients. However, the evidence about the performance indicators of the SARC-F questionnaire to screen for sarcopenia in acute patients admitted to an acute care unit is really limited.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 105
• Est. completion date: November 11, 2020
• Est. primary completion date: November 11, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Patients aged 65 and over
• Hospitalized in an acute care geriatric unit due to acute health issues or acute medical conditions
• With SARC-F, hand-grip strength and dual-energy X-ray absorptiometry administered during hospital admission

Exclusion Criteria:

• SARC-F unavailable
• Unwilling to collaborate in the sarcopenia assessment
• Unwilling to sign the informed consent

Related Conditions & MeSH terms

• Old Age; Debility
• Sarcopenia
• Sensitivity

Intervention

Diagnostic Test:
• 5-item SARC-F questionnaire
Administration of the 5-item SARC-F questionnaire in patients admitted to an acute care unit

Locations

Country	Name	City	State
Belgium	Brugmann university hospital	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Brugmann University Hospital

Country where clinical trial is conducted

Belgium, 

References & Publications (4)

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169. Erratum in: Age Ageing. 2019 Jul 1;48(4):601. — View Citation

Piotrowicz K, Gluszewska A, Czesak J, Fedyk-Lukasik M, Klimek E, Sánchez-Rodríguez D, Skalska A, Gryglewska B, Grodzicki T, Gasowski J. SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards. Aging Clin Exp Res. 2021 Jan 28. doi: 10.1007/s40520-020-01782-y. [Epub ahead of print] — View Citation

Sanchez-Rodriguez D, Marco E, Cruz-Jentoft AJ. Defining sarcopenia: some caveats and challenges. Curr Opin Clin Nutr Metab Care. 2020 Mar;23(2):127-132. doi: 10.1097/MCO.0000000000000621. — View Citation

Sánchez-Rodríguez D, Marco E, Dávalos-Yerovi V, López-Escobar J, Messaggi-Sartor M, Barrera C, Ronquillo-Moreno N, Vázquez-Ibar O, Calle A, Inzitari M, Piotrowicz K, Duran X, Escalada F, Muniesa JM, Duarte E. Translation and Validation of the Spanish Version of the SARC-F Questionnaire to Assess Sarcopenia in Older People. J Nutr Health Aging. 2019;23(6):518-524. doi: 10.1007/s12603-019-1204-z. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity of the SARC-F questionnaire as screening method compared to the gold standard, which is the revised European consensus on definition and diagnosis	Sensitivity, measured as a percentage (%)	September 2019-November 2020
Primary	Specificity of the SARC-F questionnaire as a screening method, compared to the gold standard which is the revised European Consensus on definition and diagnosis of sarcopenia (EWGSOP2)	Specificity, measured as a percentage (%)	September 2019-November 2020
Primary	Overall concordance agreement between the SARC-F questionnaire as a screening method and the gold standard method, which is the EWGSOP2	Cohen-kappa coefficient, measured as a percentage (%)	September 2019-November 2020
Secondary	Health adverse outcomes based on the screening and diagnosis of sarcopenia as recommended by the EWGSOP2	Mortality risk	1-year follow-up